Business · 21/05/2018Updated: 10/17/2026 · 1 min read
FDA Releases Guidance for Industry on Treating Male Hypogonadotropic Hypogonadism with Testosterone Therapy
Summary
The FDA has released a guidance document outlining recommendations for establishing the effectiveness of drugs intended to treat male hypogonadotropic hypogonadism, a condition associated with obesity and other non-structural disorders, and provides updates based on FDA advisory committee meetings in 2014 and 2016.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →